Meeting Summary
The 2022 NCI Alliance for Nanotechnology in Cancer Annual Principal Investigator Meeting will be held virtually on October 18-19, 2022. The meeting will gather the Alliance investigators and collaborators to present their recent research results as well as to discuss emerging opportunities in cancer nanotechnology. This year the scientific sessions will include: Cancer interventions enabled by new material designs; Novel cancer therapies based on nanotechnology; and Immunotherapies and vaccines. This year’s meeting will also feature panel discussions on topics “What will be the next nano-drug approved by FDA?” and “Can nanotechnology aid in combating cancer metastasis?”.
Agenda
DAY 1: October 18, 2022 |
|
9:00 am – 10:00 am |
Join Meeting – Computer Check |
10:00 am – 10:20 am |
Welcome and Introduction |
10:20 am – 11:00 am |
Plenary presentation |
SESSION I: CANCER INTERVENTIONS ENABLED BY NEW MATERIAL DESIGNS (PART 1) MODERATOR: Piotr Grodzinski , Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI |
|
11:00 am – 11:20 am |
The tumor microenvironment in nanoparticle delivery and function |
11:20 am – 11:40 am |
Imaging of nanotherapeutic drug action |
11:40 am – 12:00 pm |
Copper-depleting nanotheranostics for treating triple negative breast cancer |
12:00 pm – 12:20 pm |
In situ cancer cell specific biomineralization to overcome nanoparticle delivery barriers and sensitize pancreatic cancer to radiotherapy |
12:20 pm – 12:40 pm |
Fluorescent indocarbocyanine PEGylated lipid nanoparticles for understanding and |
12:40 pm – 1:10 pm |
LUNCH BREAK |
Session II. Discussion Panel: WHAT WILL BE THE NEXT NANO-DRUG APPROVED BY FDA? Moderator: Andrew Wang, M.D., UT SOUTHWESTERN MEDICAL CENTER |
|
1:10 pm – 2:10 pm |
Panel:
|
SESSION III: NOVEL CANCER THERAPIES BASED ON NANOTECHNOLOGY MODERATOR: Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI |
|
2:10 pm - 2:30 pm |
Ultrasmall particle-based solutions for inducing ferroptosis and improving antitumor immune responses in cancer |
2:30 pm - 2:50 pm |
Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis |
2:50 pm - 3:10 pm |
Nanodelivery platform for antibody drugs targeting NHL |
3:10 pm - 3:30 pm |
Towards translation of MU-CN29: New therapeutic nanoparticle for drug resistant NSCLC |
3:30 pm – 3:45 pm |
BREAK |
3:45 pm - 4:05 pm |
Targeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modeling |
4:05 pm - 4:25 pm |
TNBC ligand-displaying exosomes using RNA nanotechnology for targeted cytosol delivery of RNAi without endosome entrapment |
4:25 pm - 4:45 pm |
Novel approach to attenuate small cell lung cancer growth and metastasis |
4:45 pm - 5:00 pm |
Q&A/Day 1 Wrap-up |
DAY 2: October 19, 2022 |
|
9:00 am - 10:00 am |
Join Meeting-Computer Check |
10:00 am - 10:10 am |
Day 1 recap |
SESSION IV: CANCER INTERVENTIONS ENABLED BY NEW MATERIAL DESIGNS (PART 2) MODERATOR: Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI |
|
10:10 am - 10:30 am |
Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer |
10:30 am - 10:50 am |
The development of novel radiation-sensitizer based on ultra-small carbon dots |
10:50 am - 11:10 am |
Stimuli-responsive mucin1-specific nanoparticles for efficacious combinatorial |
11:10 am - 11:30 am |
Nanotechnology for targeted therapy and fundamental understanding of |
11:30 am - 11:50 am |
Map leukemia-immune cell talks with nanoplasmon ruler in CAR T-cell immunotherapy |
11:50 am - 12:20 pm |
LUNCH BREAK |
SESSION V: PANEL DISCUSSION: CAN NANOTECHNOLOGY AID IN COMBATING CANCER METASTASIS? Moderator: Patricia Steeg, Ph.D., CENTER FOR CANCER RESEARCH, NCI |
|
12:20 pm - 1:20 pm |
PANEL:
|
SESSION VI: IMMUNOTHERAPIES AND VACCINES MODERATOR: Leela Rani Avula, Ph.D., Program Director, NSDB, CIP, DCTD, NCI |
|
1:20 pm – 1:40 pm |
A cobalt porphyrin nanoliposome adjuvant for MHC-I-restricted cancer peptide vaccines |
1:40 pm – 2:00 pm |
Innovative research for cancer nanotechnology (IRCN) for enhancing melanoma- |
2:00 pm – 2:20 pm |
Targeting effector immune cells to cancer with chemically self-assembled nanorings (CSANs) |
2:20 pm - 2:40 pm |
BREAK |
2:40 pm – 3:00 pm |
Toward translation of an immunotherapeutic nanomedicine for neuroblastoma |
3:00 pm – 3:20 pm |
Whitlockite nanoparticle-based immunotherapy for bone metastasis |
3:20 pm – 3:40 pm |
Toward translation of a plant virus-based in situ vaccination nanotechnology |
3:40 pm- 4:00 pm |
Closing Remarks |